Login to Your Account

TCM benefits from better science, but innovation still hamstrung by tradition

By Shannon Ellis
Staff Writer

Wednesday, March 12, 2014

SHANGHAI – Bayer AG’s recent purchase of traditional Chinese medicine (TCM) maker Dihon Pharmaceutical Group Co. was viewed by some as a step closer to the legitimization of the TCM drug market, one that occupies about a third to a half of all revenues here.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription